June 14, 2023

Danny Sheng Wu Yeung Chief Executive Officer Prenetics Global Ltd Unit 701-706, K11 Atelier King s Road 728 King s Road, Quarry Bay Hong Kong

Re: Prenetics Global

Ltd

Form 20-F

Annual Report on

Filed May 1, 2023 File No. 001-41401

Dear Danny Sheng Wu Yeung:

We have reviewed your filing and have the following comments. In some of our

comments, we may ask you to provide us with information so we may better understand your $% \left(1\right) =\left(1\right) +\left(1\right) +\left$

disclosure.

Please respond to these comments within ten business days by providing the requested

information or advise us as soon as possible when you will respond. If you do not believe our

comments apply to your facts and circumstances, please tell us why in your response.

After reviewing your response to these comments, we may have additional comments.

Annual Report on Form 20-F filed on May 1, 2023

Item 3. Key Information, page 6

1. At the onset of Part I, please disclose prominently that you are not a Chinese operating company but a Cayman Islands holding company with operations conducted by your subsidiaries. In addition, please provide early in the Business section a diagram of the company s corporate structure.

2. Provide prominent disclosure about the legal and operational risks associated with being based in or having the majority of the company s operations in China. Your disclosure should make clear whether these risks could result in a material change in your operations and/or the value of your securities or could significantly limit or completely hinder your ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless. Your disclosure should address how Danny Sheng Wu Yeung Prenetics Global Ltd June 14, 2023 Page 2

recent statements and regulatory actions by China $\,$ s government, such as those related to

data security or anti-monopoly concerns, have or may impact the company s ability to

conduct its business, accept foreign investments, or list on a U.S. or other foreign

exchange. Also disclose that regulatory actions related to data security or anti-monopoly $% \left(1\right) =\left(1\right) +\left(1\right) +$

concerns in Hong Kong or Macau have or may impact your ability to conduct your

business, accept foreign investments, or list on a U.S. or foreign exchange.

3. Please disclose the location of your auditor s headquarters and

whether and how the Holding Foreign Companies Accountable Act, as amended by the Consolidated Appropriations Act, 2023, and related regulations will affect your company. We note your definitions on page 3 on how you will refer to the 4. holding company and subsidiaries when providing the disclosure throughout the document. In Part I. Item 3. Key Information section, please clearly disclose how you will refer to the holding company and subsidiaries when providing the disclosure throughout the document so that it is clear to investors which entity the disclosure is referencing and which subsidiaries or entities are conducting the business operations. For example, disclose, if true, that your subsidiaries conduct operations in China. Provide a clear description of how cash is transferred through your organization. Disclose your intentions to distribute earnings. Quantify any cash flows and transfers of other assets by type that have occurred between the holding company and its subsidiaries, and direction of transfer. Quantify any dividends or distributions that a subsidiary have made to the holding company and which entity made such transfer, and their tax consequences. Similarly quantify dividends or distributions made to U.S. investors, the source, and their tax consequences. Your disclosure should make clear if no transfers, dividends, or distributions have been made to date. Describe any restrictions on foreign exchange and your ability to transfer cash between entities, across borders, and to U.S. investors. Describe any restrictions and limitations on your ability to distribute earnings from the company, including your subsidiaries, to the parent company and U.S. investors. Disclose each permission or approval that you or your subsidiaries are required to obtain from Chinese authorities to operate your business and to offer securities to foreign investors. State whether you or your subsidiaries are covered by permissions requirements from the China Securities Regulatory Commission (CSRC), Cyberspace Administration of China (CAC) or any other governmental agency that is required to approve vour operations, and state affirmatively whether you have received all requisite permissions or approvals and whether any permissions or approvals have been denied. Please also describe the consequences to you and your investors if you or your subsidiaries: (i) do not receive or maintain such permissions or approvals, (ii) inadvertently conclude that such FirstName LastName Danny Sheng Wu Yeung permissions or approvals are not required, or (iii) applicable laws, regulations, or Comapany NamePrenetics interpretations Global Ltd are required to obtain such permissions change or approvals in the and you future. June 14, 2023 Page 2 FirstName LastName Danny Sheng Wu Yeung FirstName LastName Prenetics Global Ltd Danny Sheng Wu Yeung Comapany NamePrenetics Global Ltd June 14, 2023

Comapany
June NamePrenetics Global Ltd
14, 2023
June 14,
Page 3 2023 Page 3
FirstName LastName
Part I
Item 3. Key Information
D. Risk Factors, page 6

7. In your summary of risk factors, disclose the risks that your corporate structure and being

based in or having the majority of the company s operations in China poses to investors.

In particular, describe the significant regulatory, liquidity, and enforcement risks. For

example, specifically discuss risks arising from the legal system in China, including risks

and uncertainties regarding the enforcement of laws and that rules and regulations in

China can change quickly with little advance notice; and the risk that the Chinese

government may intervene or influence your operations at any time, or may exert more

control over offerings conducted overseas and/or foreign investment in ${\tt China-based}$

issuers, which could result in a material change in your operations and/or the value of

your securities. Acknowledge any risks that any actions by the Chinese government to

exert more oversight and control over offerings that are conducted overseas and/or foreign $% \left(1\right) =\left(1\right) \left(1\right) +\left(1\right) \left(1\right) \left(1\right) +\left(1\right) \left(1\right) \left(1\right) \left(1\right) +\left(1\right) \left(1\right) \left$

investment in China-based issuers could significantly limit or completely hinder your $% \left(1\right) =\left(1\right) +\left(1$

ability to offer or continue to offer securities to investors and cause the value of your $\,$

securities to significantly decline or be worthless.

8. Please expand your risk factors to disclose that the Holding Foreign Companies

Accountable Act, as amended by the Consolidated Appropriations Act, 2023, decreases

the number of consecutive non-inspection years from three years to two years, and thus,

reduces the time before your securities may be prohibited from trading or delisted. Update

your disclosure to describe the potential consequences to you if the $\operatorname{\mathsf{PRC}}$ adopts positions

at any time in the future that would prevent the PCAOB from continuing to inspect or $% \left(1\right) =\left(1\right) +\left(1\right$

investigate completely accounting firms headquartered in mainland China or Hong Kong.

9. We note your disclosure about having business operations in Hong Kong and not in $\,$

Mainland China and the risks that come with having direct Chinese government oversight

authority on page 20. Disclose in this Risk Factor, as you do in the Post-Effective

Amendment No. 3 to Form F-1, file no. 333-265284, dated May 31, 2023, that you believe

there is significant market opportunity for you in Mainland China for early detection of

cancer. Also, given recent statements by the Chinese government indicating an intent to $% \left(1\right) =\left(1\right) +\left(1\right) +\left($

exert more oversight and control over offerings that are conducted overseas and/or foreign $% \left(1\right) =\left(1\right) +\left(1\right)$

investment in China-based issuers, acknowledge the risk that any such action could

significantly limit or completely hinder your ability to offer or continue to offer securities

to investors and cause the value of such securities to significantly decline or be worthless.

10. In light of recent events indicating greater oversight by the Cyberspace Administration of

China (CAC) over data security, particularly for companies seeking to list on a foreign

exchange, please revise your disclosure to explain how this oversight impacts your

business and your securities and to what extent you believe that you are compliant with

the regulations or policies that have been issued by the CAC to date. Also, provide risk

factor disclosure to explain whether there are any commensurate laws or regulations in

Danny Sheng Wu Yeung

Prenetics Global Ltd

June 14, 2023

Page 4

Hong Kong or Macau which result in oversight over data security and explain how this

oversight impacts the company s business and the offering and to what

extent the

issued.

General

11. Please revise to include a separate section that discloses the information required by Item

101(g) of Regulation S-K. Include Summary Risk Factor and Risk Factor disclosure

discussing where your executive officers and directors are located, specifically addressing

the difficulty of bringing actions against individuals located in China (or other foreign

jurisdictions) and enforcing judgments against them.

12. We note your definition of "mainland China" excludes Hong Kong and Macau. Please

revise to clarify that the legal and operational risks associated with operating in China also

apply to operations in Hong Kong and Macau.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

You may contact Al Pavot at 202-551-3738 or Terence O'Brien at 202-551-3355 if you have questions regarding comments on the financial statements and related matters. Please contact Nicholas O'Leary at 202-551-4451 or Margaret Schwartz at 202-551-7153 with any other questions.

Sincerely,

FirstName LastName Danny Sheng Wu Yeung Corporation Finance Division of Office of

Industrial Applications and Comapany NamePrenetics Global Ltd

Services

June 14, 2023 Page 4

cc: Jonathan Stone, Esq.

FirstName LastName